PRODUCT · SERVICE PLATFORM
PortraiMOA
Analyze the genes that go up and down when your drug acts.
Mechanism-of-action analysis built for licensing and asset evaluation. PortraiMOA reads which genes a candidate moves — and where in the tissue it moves them — with the spatial context that matters for solid tumors and brain disease.
- DELIVERABLE
- Interactive Report
- TYPICAL TIMELINE
- ~16 weeks
- BUILT FOR
- Licensing · Asset evaluation
WHY PORTRAIMOA
Mechanism is local. Licensing decisions should be too.
Bulk MoA misses where the drug actually does its work. PortraiMOA grounds the analysis in spatial transcriptomics so efficacy and side-effect signals are read in the tissue context licensing teams care about.
- 01
Spatial context for hard indications
Solid tumors and brain disease both care where the drug acts, not just whether it acts. Spatial transcriptomics surfaces local effect, off-target spillover, and microenvironment response in one view.
- 02
Licensing-grade insight
Built for the questions BD and licensing teams actually ask — efficacy vs side-effect comparison, asset differentiation, and the evidence package decision-makers want.
- 03
Interactive Report deliverable
Output is an Interactive Report — not a static PDF. Stakeholders explore the gene-effect maps, drill into tissue regions, and revisit findings as the asset case evolves.
WHAT IT DOES
From candidate to mechanism evidence
Four analyses that turn a drug-action question into a defensible licensing or evaluation case.
- Effect signal
Drug-effect gene analysis
Identifies the genes a candidate increases or decreases in treated tissue, with spatial resolution — so the effect is read where the drug actually reached.
- Asset triage
Efficacy vs side-effect comparison
Compares on-target vs off-target signatures across treatment arms, surfacing the side-effect risk profile alongside the efficacy story.
- BD-ready
Licensing-decision evidence
Frames the analysis around the questions licensing teams ask — comparator differentiation, indication-specific signal, and asset-stage readouts.
- Solid tumor · CNS
Indication-aware analysis
Tuned for the indications where spatial context is non-negotiable — solid tumors and brain diseases where local concentration and microenvironment determine the response.
WORKFLOW
From kickoff to report in ~16 weeks
A scoped consulting engagement, not a SaaS subscription. Each step is anchored to a stakeholder conversation so the deliverable stays decision-relevant.
01 — Stakeholder consultation
Drug-specific inquiries are mapped to spatial transcriptomics questions. We align on what "actionable" looks like for your team before scope is set.
02 — Scope & direction
Analysis scope, comparators, and tissue context defined. Sample requirements and timeline are confirmed against the licensing or evaluation deadline.
03 — Spatial MoA analysis
Drug-effect gene analysis runs on the agreed samples — efficacy, side-effect comparison, and indication-specific readouts in spatial context.
04 — Interactive Report
Findings shipped as an Interactive Report — not a static PDF. Stakeholders explore tissue regions, drill into gene-effect maps, and revisit findings.
USE CASES
Who PortraiMOA is built for
BD, licensing, and asset-evaluation teams that need spatial-grade mechanism evidence — without standing up a spatial transcriptomics group internally.
Licensing decisions
Spatial mechanism evidence for in-licensing or out-licensing reviews — comparator differentiation and indication-specific signal in one report.
Asset evaluation
Pre-acquisition or pipeline-prioritization reviews where bulk MoA falls short — solid tumor and CNS assets read on the spatial biology that drives the indication.
Differentiation vs comparators
Side-by-side comparison against benchmark or competitor compounds — the gene-effect spatial signature that distinguishes the asset.
READY TO EVALUATE?
Read your asset's mechanism in the tissue that matters.
Talk to our BD team about scoping a PortraiMOA engagement for your asset — typical timeline ~16 weeks from kickoff to Interactive Report.